Not All COVID Patients Benefit From JAK Inhibitor – Medpage Today

People randomized to the Janus kinase (JAK) inhibitor baricitinib (Olumiant) to treat COVID-19 pneumonia in a clinical trial only saw a survival benefit if they had obesity, a post-hoc analysis found.

Death within 28 days of starting treatment occurred in 5.6% of patients with body mass index (BMI) values >30, compared with 9.2% of those assigned to placebo, according to Dennis G. McGonagle, MBBCh, PhD, of the University of Leeds in England, and colleagues.

That translated to an age-adjusted rate ratio of 0.6 (P<0.05), the group reported in RMD Open. A similar gap was seen in overweight patients (BMI 25 and 30).

In contrast, the same comparison made in patients with BMI <25 yielded survival rates of 6.6% with baricitinib versus 8.1% in the placebo group, which missed the P<0.05 threshold. The nonsignificance was not easily attributable to small sample size, as there were 120 and 132 patients with normal-range BMI assigned to baricitinib and placebo, respectively, and a total of 26 deaths among them.

The new findings come from an age- and BMI-stratified analysis of data from the multinational COV-BARRIER trial, conducted early in the pandemic, in which a total of 1,525 patients with COVID-19 pneumonia needing oxygen support were randomized to baricitinib or placebo on top of standard treatments including antivirals and/or corticosteroids. (Primary results were published here in 2021.) Approximately 17% of each arm were in the normal BMI range; roughly 40% were overweight and the remainder had obesity.

Overall, 162 patients died within 28 days, although seven of these were excluded from the analysis because data on BMI and age were missing. Most of the deaths occurred in patients 65 and older, who represented 30% of the total sample.

The investigators had no solid explanation for how excess body fat could make baricitinib more effective in COVID-19 pneumonia. In previous studies, COVID-19, obesity, and JAK inhibition all appeared to promote thrombosis, such that baricitinib ought to worsen, not improve, survival in COVID patients with overweight/obesity. Responses to JAK inhibitors in rheumatologic diseases have, indeed, been found to be worse among individuals with obesity.

"[O]ur findings are remarkable and suggest a hitherto unappreciated mechanism for this 'JAK thrombosis-related paradox,'" McGonagle and colleagues wrote. The group suggested that coagulability and thrombosis associated with obesity are key factors: "[T]his population has poorer tissue oxygenation and suffers more from COVID-19 immunothrombosis that is controlled when treated with baricitinib and standard COVID-19 therapy," they noted. In particular, the researchers argued that the use of corticosteroids alongside baricitinib may account for the "counterintuitive" results.

John Gever was Managing Editor from 2014 to 2021; he is now a regular contributor.

Disclosures

COV-BARRIER was funded by Eli Lilly but the company was not involved in the post-hoc analysis except to provide the data. Authors declared they had no relevant financial interests.

Primary Source

RMD Open

Source Reference: David P, et al "Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects" RMD Open 2024; DOI: 10.1136/rmdopen-2023-004045.

Read this article:

Not All COVID Patients Benefit From JAK Inhibitor - Medpage Today